Boehringer Ingelheim Kg

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim Zentrale

Erich Lehr

Karl-Heinz Weber

Franz J Kuhn

Gerhard Walther

Claus S Schneider

Helmut Ensinger

Dieter Hinzen

Werner Stransky

Gunter Schingnitz

Wolfgang Troger

Ulrike Kufner-Muhl

Wolf-Dietrich Bechtel

Joachim Mierau

Adolf Langbein

Karin Boke-Kuhn

Karin Boke

Matthias Hoffmann

Wolfram Gaida

Gerald Pohl

Thomas Weiser

Stefan Matthias Blech

Adrian Carter

Enzio Muller

Ulrike Kuefner-Muehl

Albrecht Harreus

Werner Kummer

Christopher John Montague Meade

Rudolf Hammer

Adolf Bauer

Franz-Josef Kuhn

Wilhelm Frolke

Astrid Schuster

Gerhard Waither

Franco Borsini

Gerhard Walther, Deceased

Ursula Gath

Imidazotriazolopyrimidines with adenosine-antagonistic activity

The invention relates to the use of pramipexol as a pharmaceutical composition having an antidepressant activity.

Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity

Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity

Xanthine derivatives of formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or alkynyl, R.sub.2 is different and is alkyl, alkynyl, phenyl-alkylene, phenyl alkenylene, cycloalkyl, inter alia, R.sub.3 is cycloalkyl, phenyl, norbornane, inter alia and R.sub.4 is hydrogen, methyl, benzyl, inter alia.

Asymmetrically substituted xanthines

The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.

Xanthine derivatives with adenosine-antagonistic activity

Bornyl xanthine derivatives with adenosine-antagonistic activity

New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.

8-substituted 1,3-dialiphaticxanthine derivatives

Xanthines of the formula I ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group:

The invention relates to new tetrahydropyridine derivatives, processes for preparing them and their use as pharmaceutical compositions with cholinomimetic properties.

Tetrahydropyridine derivatives

An improved process for employing tricyclic antidepressants involving co-administration of a N-benzyl-pyrrolidin-2-one.

Agent with an antidepressant activity

Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 4 carbon atoms; R.sub.2 is 2-, 3- or 4-pyridyl, phenyl or mono- or di-substituted phenyl, where the substituents are each individually alkoxy of 1 to 2 carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, alkyl or 1 to 4 carbon atoms, hydroxyl or nitro; and

N-heterocyclic substituted -pyrrolidin-2-ones

1-(benzyl or pyridylmethyl)-4 or 5-aminomethyl-pyrrolidin-2-ones

Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 4 carbon atoms;

1-benzyl-4- or 5-pyrrolidinomethyl-pyrrolidin-2-ones and nootropic

The invention relates to the use of 1-benzyl-aminoalkyl-pyrrolidinones as antidepressants.

Use of 1-benzyl-aminoalkyl-pyrrolidinones as antidepressants

Growing community of inventors

Waldalgesheim, Germany

Erich Lehr